Cargando…

Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction

BACKGROUND: This study was designed to prospectively evaluate the efficacy of extracorporeal photopheresis (ECP) to attenuate the rate of decline of FEV(1) in lung transplant recipients with refractory bronchiolitis obliterans. Due to an observed higher than expected early mortality, a preliminary a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hage, Chadi A., Klesney‐Tait, Julia, Wille, Keith, Arcasoy, Selim, Yung, Gordon, Hertz, Marshall, Chan, Kevin M., Morrell, Matt, Goldberg, Hilary, Vedantham, Suresh, Derfler, Mary Clare, Commean, Paul, Berman, Keith, Spitznagel, Ed, Atkinson, Jeff, Despotis, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453798/
https://www.ncbi.nlm.nih.gov/pubmed/33955079
http://dx.doi.org/10.1111/tme.12779
_version_ 1784570348891537408
author Hage, Chadi A.
Klesney‐Tait, Julia
Wille, Keith
Arcasoy, Selim
Yung, Gordon
Hertz, Marshall
Chan, Kevin M.
Morrell, Matt
Goldberg, Hilary
Vedantham, Suresh
Derfler, Mary Clare
Commean, Paul
Berman, Keith
Spitznagel, Ed
Atkinson, Jeff
Despotis, George
author_facet Hage, Chadi A.
Klesney‐Tait, Julia
Wille, Keith
Arcasoy, Selim
Yung, Gordon
Hertz, Marshall
Chan, Kevin M.
Morrell, Matt
Goldberg, Hilary
Vedantham, Suresh
Derfler, Mary Clare
Commean, Paul
Berman, Keith
Spitznagel, Ed
Atkinson, Jeff
Despotis, George
collection PubMed
description BACKGROUND: This study was designed to prospectively evaluate the efficacy of extracorporeal photopheresis (ECP) to attenuate the rate of decline of FEV(1) in lung transplant recipients with refractory bronchiolitis obliterans. Due to an observed higher than expected early mortality, a preliminary analysis was performed. STUDY DESIGN AND METHODS: Subjects from 10 lung transplant centres were assigned to ECP treatment or to observation based on spirometric criteria, with potential crossover for those under observation. The primary endpoint of this study was to assess response to ECP (i.e., greater than a 50% decrease in the rate of FEV(1) decline) before and 6 months after initiation of ECP. Mortality was also evaluated 6 and 12 months after enrolment as a secondary endpoint. RESULTS: Of 44 enrolled subjects, 31 were assigned to ECP treatment while 13 were initially assigned to observation on a non‐random basis using specific spirometric inclusion criteria (seven of the observation patients subsequently crossed over to receive ECP). Of evaluable patients, 95% of patients initially assigned to treatment responded to ECP with rates of FEV(1) decline that were reduced by 93% in evaluable ECP‐treated patients. Mortality rates (percentages) at 6 and 12 months after enrolment was 32% and 41%, respectively. The most common (92%) primary cause of death was respiratory or graft failure. Significantly (p = 0.002) higher rates of FEV(1) decline were observed in the non‐survivors (−212 ± 177 ml/month) when compared to the survivors (−95 ± 117 ml/month) 12 months after enrolment. In addition, 18 patients with bronchiolitis obliterans syndrome (BOS) diagnosis within 6 months of enrolment had lost 38% of their baseline lung function at BOS diagnosis and 50% of their lung function at enrolment. CONCLUSIONS: These analyses suggest that earlier detection and treatment of BOS should be considered to appreciate improved outcomes with ECP.
format Online
Article
Text
id pubmed-8453798
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-84537982021-09-27 Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction Hage, Chadi A. Klesney‐Tait, Julia Wille, Keith Arcasoy, Selim Yung, Gordon Hertz, Marshall Chan, Kevin M. Morrell, Matt Goldberg, Hilary Vedantham, Suresh Derfler, Mary Clare Commean, Paul Berman, Keith Spitznagel, Ed Atkinson, Jeff Despotis, George Transfus Med Original Articles BACKGROUND: This study was designed to prospectively evaluate the efficacy of extracorporeal photopheresis (ECP) to attenuate the rate of decline of FEV(1) in lung transplant recipients with refractory bronchiolitis obliterans. Due to an observed higher than expected early mortality, a preliminary analysis was performed. STUDY DESIGN AND METHODS: Subjects from 10 lung transplant centres were assigned to ECP treatment or to observation based on spirometric criteria, with potential crossover for those under observation. The primary endpoint of this study was to assess response to ECP (i.e., greater than a 50% decrease in the rate of FEV(1) decline) before and 6 months after initiation of ECP. Mortality was also evaluated 6 and 12 months after enrolment as a secondary endpoint. RESULTS: Of 44 enrolled subjects, 31 were assigned to ECP treatment while 13 were initially assigned to observation on a non‐random basis using specific spirometric inclusion criteria (seven of the observation patients subsequently crossed over to receive ECP). Of evaluable patients, 95% of patients initially assigned to treatment responded to ECP with rates of FEV(1) decline that were reduced by 93% in evaluable ECP‐treated patients. Mortality rates (percentages) at 6 and 12 months after enrolment was 32% and 41%, respectively. The most common (92%) primary cause of death was respiratory or graft failure. Significantly (p = 0.002) higher rates of FEV(1) decline were observed in the non‐survivors (−212 ± 177 ml/month) when compared to the survivors (−95 ± 117 ml/month) 12 months after enrolment. In addition, 18 patients with bronchiolitis obliterans syndrome (BOS) diagnosis within 6 months of enrolment had lost 38% of their baseline lung function at BOS diagnosis and 50% of their lung function at enrolment. CONCLUSIONS: These analyses suggest that earlier detection and treatment of BOS should be considered to appreciate improved outcomes with ECP. Blackwell Publishing Ltd 2021-05-05 2021-08 /pmc/articles/PMC8453798/ /pubmed/33955079 http://dx.doi.org/10.1111/tme.12779 Text en © 2021 The Authors. Transfusion Medicine published by John Wiley & Sons Ltd on behalf of British Blood Transfusion Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Hage, Chadi A.
Klesney‐Tait, Julia
Wille, Keith
Arcasoy, Selim
Yung, Gordon
Hertz, Marshall
Chan, Kevin M.
Morrell, Matt
Goldberg, Hilary
Vedantham, Suresh
Derfler, Mary Clare
Commean, Paul
Berman, Keith
Spitznagel, Ed
Atkinson, Jeff
Despotis, George
Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction
title Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction
title_full Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction
title_fullStr Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction
title_full_unstemmed Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction
title_short Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction
title_sort extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453798/
https://www.ncbi.nlm.nih.gov/pubmed/33955079
http://dx.doi.org/10.1111/tme.12779
work_keys_str_mv AT extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction
AT hagechadia extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction
AT klesneytaitjulia extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction
AT willekeith extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction
AT arcasoyselim extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction
AT yunggordon extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction
AT hertzmarshall extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction
AT chankevinm extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction
AT morrellmatt extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction
AT goldberghilary extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction
AT vedanthamsuresh extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction
AT derflermaryclare extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction
AT commeanpaul extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction
AT bermankeith extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction
AT spitznageled extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction
AT atkinsonjeff extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction
AT despotisgeorge extracorporealphotopheresistoattenuatedeclineinlungfunctionduetorefractoryobstructiveallograftdysfunction